Antibody avidity meets many myeloma In the continued hunt for innovative remedies to overcome refractory and relapsed cancer, new preclinical get the job done in numerous myeloma displays that expanding binding avidity by concentrating on two antigens in a single T mobile-partaking trispecific antibody boosts anti-tumor exercise and lowers the chan